Tri-Regol

Selected form

Method of action: Contraceptive, Endocrine Therapy, Estrogen-Progestational, Sex Hormones And Modulators Of The Genital System

Treatment option: Hormonal Contraceptives, Venous Thromboembolism, Birth Control, Thromboembolism

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tri-Regol

Property	Description
Active Ingredients	Ethinyl Estradiol, Levonorgestrel
Form	Coated tablets (Oral)
Pharmacological Class	Hormonal contraceptives for systemic use
Common Use	Contraception (Birth control)
Origin	Synthetic (Laboratory-derived hormones)

What Type of Medicine is Tri-Regol?

Tri-Regol is classified as a combined oral hormonal contraceptive (COHC), a synthetic medicine intended for systemic use throughout the body. The fundamental purpose of this prescription medicine is reliable contraception, or the prevention of pregnancy. Its pharmacological class is defined as progestogens and estrogens, combined. This dual-hormone approach is clinically recognized for its high efficacy in reproductive control and is frequently provided to women of childbearing potential who require a dependable, reversible method of birth control.

Composition and The Triphasic Structure

The active core of Tri-Regol is a combination of two synthetic hormones: Ethinyl Estradiol (a synthetic estrogen) and Levonorgestrel (a synthetic progestogen). This composition places it within the category of second-generation combined oral contraceptives, a group supported by extensive pharmacological studies. The medicine is delivered in the form of coated tablets taken orally. The product's distinctive feature is its triphasic structure, where it provides three different dose levels of hormones across the cycle. This variable dosing structure is intended to potentially offer improved cycle predictability compared to fixed-dose monophasic options.

How Tri-Regol Works to Prevent Pregnancy

The combined synthetic hormones in Tri-Regol ensure the prevention of conception by triggering a simultaneous, multi-level physiological action. The primary mechanism involves stopping ovulation, meaning the ovary is prevented from releasing an egg. Additionally, the hormones cause a significant thickening of the cervical mucus, which creates a hostile environment that restricts sperm movement. These processes, combined with the alteration of the endometrium (womb lining), confirm the product's effectiveness as a systemic birth control method.

Regulatory References

NIH: Combined Estrogen-Progestogen Contraceptives

What side effects are possible with Tri-Regol?

Possible Side Effects and Safety Information

Serious Adverse Reactions and Restrictions

Use of Tri-Regol, a combined oral contraceptive containing ethinylestradiol and levonorgestrel, is associated with a documented increased risk of serious vascular events. These include Venous Thromboembolism (VTE), such as deep vein thrombosis and pulmonary embolism, and Arterial Thromboembolism (ATE), such as myocardial infarction and stroke. The risk of VTE is highest during the first year of use, or when restarting after a break of four weeks or more.

Contraindications, as defined by regulatory authorities, strictly prohibit use in patients with a current or past history of VTE or ATE, existing prodromal conditions of thrombosis (e.g., angina pectoris, transient ischaemic attack), severe hepatic disease, liver tumours, known or suspected sex-steroid influenced malignancies (e.g., breast cancer), or migraine with focal neurological symptoms. Smoking, particularly in women over 35 years of age, is identified as a major risk factor for serious cardiovascular events.

Documented Adverse Reactions

The frequency of adverse reactions follows standard regulatory classifications (Very Common, Common, Uncommon, Rare, Very Rare). Adverse reactions are classified by System-Organ Class, involving:

Frequency	Common Adverse Reactions (Affecting 1 to 10 in 100 users)
Common	Headache, Nausea, Abdominal pain, Mood changes, Depression, Breast tenderness, Metrorrhagia, Acne, Chloasma, Weight increased
Uncommon	Migraine, Vomiting, Diarrhoea, Fluid retention, Hypertension, Breast enlargement, Rash, Urticaria
Rare	Venous Thromboembolism (VTE), Hypersensitivity, Contact lens intolerance, Weight decreased

Other adverse events, including those with rare or very rare frequency, involve the nervous system (e.g., cerebrovascular accident), hepatobiliary disorders (e.g., hepatic adenoma), and immune system disorders (e.g., exacerbation of hereditary angioedema). Regular medical check-ups, including blood pressure monitoring, are noted as necessary safety measures during treatment. Immediate cessation is required if a thrombotic event or other severe reaction is suspected.

Overdose and Emergency Response

Overdose and When to Seek Help

The following information on Tri-Regol (levonorgestrel and ethinyl estradiol) overdose is strictly based on data documented in official governmental regulatory sources.

Documented Acute Manifestations

Official regulatory documents state that the most common signs and symptoms following an acute overdose of combined oral contraceptives like Tri-Regol are:

Nausea
Vomiting
Withdrawal bleeding (may occur in females)

Clinical and Emergency Actions

Classification	Regulatory Statement
Severity	Serious adverse effects have not been reported following acute overdose, even in young children.
Antidote	No specific antidote is available for Tri-Regol overdose.
Management	Treatment should be symptomatic and supportive.

When to Seek Urgent Medical Help

According to official instructions, individuals who have taken an overdose should seek medical help or contact a Poison Control Center right away. Management is focused on the symptomatic relief of the documented manifestations.

Summary

The overdose profile is defined by a limited number of acute, non-life-threatening symptoms. Regulatory guidance mandates seeking urgent medical attention primarily for assessment and supportive care, consistent with the reported absence of severe outcomes following acute exposure.

Therapeutic Uses of Tri-Regol

What Tri-Regol Treats: Main Uses and Benefits

The medicine is commonly used to help with systemic reproductive control and is considered relevant in areas of Gynecological Symptom Management.

Reliable Contraception and Cycle Stability

The fundamental therapeutic benefit is the provision of support for the prevention of unintended pregnancy. It is generally used by women who seek a dependable, daily method, which may assist in easing the overall symptom load related to reproductive concerns and helps with long-term planning. The medicine is commonly used to help with menstrual cycle irregularity and menorrhagia (excessive blood loss). The indications include supportive relief for irregular periods, heavy menstrual bleeding, and painful menstruation.

“It provides symptomatic relief by establishing a predictable bleeding schedule and supporting functional stability during the menstrual cycle.”

This contribution to cycle management supports general well-being during symptomatic phases.

Symptom Relief for Dysmenorrhea

Tri-Regol is relevant for addressing symptoms that create noticeable physiological strain, related to dysmenorrhea, or severe menstrual cramping. It is commonly used to provide supportive therapeutic benefit for painful menstruation, assists with maintaining functional stability, and supports the patient during difficult episodes by easing distress.

Quick Fact: Symptom Management for Painful Periods Tri-Regol is commonly used to help manage symptoms related to dysmenorrhea, assisting with maintaining functional stability when cramps become more noticeable.

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Tri-Regol?

Tri-Regol, a combination oral contraceptive pill, is generally prescribed for preventing pregnancy in women of childbearing age. Like all hormonal contraceptives, its suitability depends on an individual’s medical history and current health status.

Who Can Use Tri-Regol?

Healthy women seeking a reliable, reversible method of contraception.
Women who can commit to taking the pill daily as directed.

Who Cannot Use Tri-Regol?

This medication is contraindicated (should not be used) in individuals with certain medical conditions due to increased health risks. A healthcare provider must assess these risks.

Condition Category	Examples of Contraindications
Cardiovascular/Thromboembolic	A history of, or current blood clots (e.g., DVT, PE), stroke, heart attack, or certain heart valve disorders or rhythm problems.
Hormone-Sensitive Cancers	Known or suspected breast cancer or other estrogen- or progestin-sensitive cancers.
Liver Disease	Severe liver impairment or liver tumors.
Other Serious Conditions	Unexplained vaginal bleeding, uncontrolled high blood pressure, severe diabetes with vascular symptoms, or migraine with aura.

Note: Smoking significantly increases the risk of serious cardiovascular side effects, especially in women over 35 using combination pills.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Tri-Regol focuses on pharmacokinetic alterations that modify the plasma concentrations of the active hormones, Ethinyl Estradiol and Levonorgestrel, and certain co-administered medicines.

Classification	Interacting Agents / Classes	Official Outcome Description
Contraindicated Combinations	Specific Hepatitis C virus (HCV) drug regimens; Oral Tranexamic Acid.	Prohibited co-administration due to the documented risk of liver enzyme elevation or pharmacodynamic synergism leading to increased thrombotic risk.
Reduced Hormone Exposure	CYP Enzyme Inducers (e.g., Rifampicin, Carbamazepine, St. John’s Wort).	Increased metabolic clearance of Ethinyl Estradiol and Levonorgestrel, leading to a reduction in systemic exposure.
Altered Co-Drug Levels	Lamotrigine; Caffeine; Ascorbic Acid; Acetaminophen.	Tri-Regol reduces the concentration of Lamotrigine. It may increase the plasma concentration of Caffeine. Atypical competition with Ascorbic Acid and Acetaminophen may increase Ethinyl Estradiol exposure.
Timing Constraints	Colesevelam (Bile Acid Sequestrant).	Requires separation of administration to avoid documented interference with the hormone’s absorption in the gastrointestinal tract.

Interaction-Related Restrictions

The product is formally restricted, constituting a contraindication, for use by women over 35 years old who engage in Tobacco Smoking. This restriction is based on the significant increase in the documented risk of serious cardiovascular thrombotic events. Conditions like severe vomiting or diarrhoea are also noted to potentially reduce hormone absorption.

Mechanism of Action

How Tri-Regol Works

Tri-Regol contains the active hormonal components, levonorgestrel (a progestin) and ethinyl estradiol (a synthetic estrogen). The overall mechanism of action involves the combined pharmacodynamic effects of both compounds.

Ethinyl estradiol acts via a negative feedback loop on the hypothalamic-pituitary-ovarian (HPO) axis, primarily targeting the pituitary gland. This action serves to reduce the pulsatile release of gonadotropins—specifically Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH). The resulting system-level physiological consequence is the inhibition of follicular development and subsequent ovulation.

Levonorgestrel contributes by eliciting localized effects on the reproductive tract. This includes increasing the viscosity and reducing the permeability of cervical mucus, physically impeding cellular transit. Additionally, levonorgestrel induces structural and biochemical alterations within the endometrial lining, further modulating the local reproductive environment.

Dosage and Administration Information

How Tri-Regol is Used

The administration of Tri-Regol is governed by a precise, cyclic, and sequential regimen of oral coated tablets. The primary requirement is to take one tablet daily at approximately the same time each day for 21 consecutive days, followed by a mandatory 7-day tablet-free interval. Consistency in daily timing is essential for maintaining hormonal suppression.

Dosing and Cycle Structure

The medicine is a triphasic contraceptive, meaning the active ingredients—Ethinyl Estradiol and Levonorgestrel—are delivered at three different dosage levels. Therefore, the tablets must be taken in the exact sequence indicated on the blister pack to follow the programmed hormone progression.

Tablet Phase	Number of Tablets	Ethinyl Estradiol (EE)	Levonorgestrel (LNG)
Phase 1 (Pink)	6	30 mcg	50 mcg
Phase 2 (White)	5	40 mcg	75 mcg
Phase 3 (Ochre)	10	30 mcg	125 mcg

After completing the 21 active tablets, a 7-day tablet-free period follows, during which a withdrawal bleed typically occurs. The subsequent 21-day pack must be started on the 8th day, irrespective of whether the bleeding has stopped.

Initiation and Missed Tablets

Starting the first pack on the first day of the menstrual period (Day 1 start) provides immediate administration coverage. If starting on Days 2–5 of the cycle, the use of a nonhormonal barrier method is advised concurrently for the first 7 consecutive days of active tablet-taking. Instructions for handling missed tablets are detailed and depend on the time delay and the week of the cycle, often requiring seven days of uninterrupted active tablet intake to ensure continued hormonal effect.

Recent Clinical Evidence

Tri-Regol: Recent Clinical Evidence

The research evidence for combined oral contraceptives like Tri-Regol primarily stems from Randomized Controlled Trials (RCTs) and multicenter clinical investigations focused on healthy adult women of childbearing potential. These studies are designed to measure contraceptive efficacy using methods like the Pearl Index and to monitor the degree of ovarian suppression. While reports describe measurements of efficacy within the expected ranges for this drug class, comparative evidence remains insufficient to draw strong conclusions about whether the triphasic structure offers a significantly different pattern of efficacy compared to fixed-dose (monophasic) oral contraceptives.

Studies also explore the association of this medicine's use with menstrual cycle changes. Research examined outcomes related to the bleeding profile, such as the incidence of unscheduled spotting or breakthrough bleeding. Findings from systematic reviews have been mixed, largely because the methods used to measure and report cycle disturbances varied across individual trials. This limits the ability to conclusively establish a clear advantage for the triphasic formulation in cycle management.

Research has also explored the association of the medicine's use with secondary conditions like dysmenorrhea (painful periods) and acne vulgaris. The observed changes in these symptoms are generally documented as secondary outcomes within trials focused on contraception. Dedicated, large-scale RCTs specifically designed to evaluate the triphasic formulation for symptomatic management are not commonly available, meaning certainty remains low regarding these specific outcomes. Furthermore, long-term effects beyond one year are not fully established, as follow-up durations in many core studies were limited.

Frequently Asked Questions (FAQ)

Common questions about Tri-Regol (FAQ)

Q: How does Tri-Regol compare to a monophasic pill?

According to official regulatory documents, the available evidence is insufficient to conclude that the triphasic (three-dose) structure offers a significantly different pattern of effectiveness or cycle predictability compared to standard fixed-dose (monophasic) oral contraceptives.

Q: Do I need to stop taking my pack if I have severe vomiting or diarrhea?

If severe vomiting or diarrhea occurs within 3 to 4 hours of taking an active tablet, the absorption of the hormones may be incomplete. Official advice suggests taking a new active tablet immediately. If the second tablet is also affected, the instructions for handling a missed tablet should be consulted.

Q: What is the risk of getting a blood clot while on Tri-Regol?

The use of any combined hormonal contraceptive is associated with a documented increased risk of serious vascular events, such as blood clots (Venous Thromboembolism or VTE). Official information indicates that this risk is highest during the first year of use, and also when restarting the pill after a break of four weeks or more.

Q: Can I use Tri-Regol for my acne?

The primary purpose of this medicine is contraception (preventing pregnancy). While changes in skin conditions like acne have been observed in clinical trials, this was tracked as a secondary outcome. Dedicated, large-scale studies focused on symptomatic management for acne are not commonly available, meaning certainty about this specific benefit remains low.

Q: Can Tri-Regol affect my sex drive (libido)?

Changes in libido (sex drive) are reported as a documented undesirable or less common adverse reaction for this medicine. This effect is based on findings listed in the official product information.

Q: What should I do if I forget to start my new pack on the correct day?

If the tablet-free interval is extended and the new pack is started late, the risk of pregnancy is increased. The first tablet of the new pack should be taken as soon as remembered. Official guidance advises the concurrent use of a non-hormonal barrier method for the next 7 consecutive days of active pill-taking.

Q: Does taking Vitamin C or painkillers affect my pill?

Official information lists both Ascorbic Acid (Vitamin C) and Acetaminophen (a common painkiller) as interacting agents. These may compete with the pill's hormones, which may increase the plasma concentration of Ethinyl Estradiol. Official product information on this interaction does not specifically address contraceptive efficacy.

Q: How long does it take for Tri-Regol to fully work?

Contraceptive protection is immediate if the first pack is started on the first day (Day 1) of the menstrual period. If the pack is started on Days 2–5 of the cycle, the concurrent use of a non-hormonal barrier method is advised for the first 7 consecutive days of active tablet-taking.

How should Tri-Regol be stored and disposed of?

How to Store and Dispose of Tri-Regol

The storage and disposal of Tri-Regol must strictly follow official regulatory requirements to maintain product stability and ensure public safety.

Storage Requirements

The coated tablets must be stored at a temperature below 25°C. The medicine should be kept in its original packaging and must not be used after the expiry date (EXP) printed on the carton and blister. For safety, Tri-Regol must always be kept out of the sight and reach of children.

Disposal Instructions

Official guidelines state that unused or expired Tri-Regol must not be thrown away with household waste or disposed of via wastewater. To ensure proper pharmaceutical waste handling, patients are directed to ask a pharmacist for the correct procedure for discarding the medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.